Results 131 to 140 of about 2,175,372 (155)

The MASTL/YBX1/PAK4 axis regulated by stress-activated STK24 triggers lenvatinib resistance and tumor progression in HCC. [PDF]

Hepatology
Liang BG, Zheng YM, Xu MH, Gao C, Xu WX, Chen JB, Wang SW, Zhao LT, Yang GH, Yuan L, Ma AY, Dong ZN, Cai JB, Sun HC, Ke AW, Shen YH.   +15 more
europepmc   +1 more source

Regulated Cell Death in Lenvatinib Resistance of Hepatocellular Carcinoma: from Molecular Mechanisms to Therapeutic Strategies. [PDF]

Int J Biol Sci
Chen R, Hu X, Huang Y, Jiang Y, Chen G, Shan Q, Xu X, Zheng S.   +7 more
europepmc   +1 more source

Inhibition of nuclear receptor coactivator 5 overcomes acquired lenvatinib resistance driven by protein kinase B-mammalian target of rapamycin signaling in hepatocellular carcinoma. [PDF]

Anticancer Drugs
Zhou H, Zhang Q, Yang L, Pan Z, Zheng H, Zhang Z, Li D, Li G, Liu X, Bao X, Liu C, Zhang W.   +11 more
europepmc   +1 more source

GALNT6 drives lenvatinib resistance in hepatocellular carcinoma through autophagy and cancer-associated fibroblast activation. [PDF]

Cell Oncol (Dordr)
Zhang P, Chen S, Cai J, Song L, Quan B, Wan J, Zhu G, Wang B, Yang Y, Zhou Z, Li T, Dai Z.   +11 more
europepmc   +1 more source

NOVA2 regulates the properties of liver cancer stem cells and lenvatinib resistance in hepatocellular carcinoma via the Wnt pathway. [PDF]

J Gastrointest Oncol
Cao JZ, Wang CQ, Shi Z, Song JY, Tustumi F, de Castria TB, Wu J, Pocha C, Tsilimigras DI, Wang ZH, Tao T, Lu J.   +11 more
europepmc   +1 more source

Deubiquitination of CIB1 by USP14 promotes lenvatinib resistance via the PAK1-ERK1/2 axis in hepatocellular carcinoma. [PDF]

Int J Biol Sci
Xu MH, Zheng YM, Liang BG, Xu WX, Cao J, Wang P, Dong ZY, Zhou CH, Sun HC, Ren N, Ke AW, Shen YH.   +11 more
europepmc   +1 more source

Proceedings of the Conference ‘Resistance 2011’

, 2011
Insecticide Resistance Action Committee, IRAC
core  

Some of the next articles are maybe not open access.

Related searches:

Resistance of Lenvatinib in Hepatocellular Carcinoma

Current Cancer Drug Targets, 2022
Qiuran Xu, Junjun Zhao
exaly  

METTL3-mA-EGFR-axis drives lenvatinib resistance in hepatocellular carcinoma

Cancer Letters, 2023
Jihui Huo
exaly  

circRNA circMED27 acts as a prognostic factor and mediator to promote lenvatinib resistance of hepatocellular carcinoma

Molecular Therapy - Nucleic Acids, 2022
Jing Wu, Peihao Wen, Yilin Wang
exaly